Novartis AG
NVSEF
$106.50
-$3.64-3.30%
OTC PK
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 0.61% | 2.57% | |||
| Total Other Revenue | -4.44% | 16.05% | |||
| Total Revenue | 0.46% | 2.93% | |||
| Cost of Revenue | -2.72% | 2.25% | |||
| Gross Profit | 1.48% | 3.15% | |||
| SG&A Expenses | -12.68% | 11.78% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | 32.14% | 1,300.00% | |||
| Total Operating Expenses | -7.37% | 8.40% | |||
| Operating Income | 18.77% | -7.94% | |||
| Income Before Tax | 34.16% | -2.95% | |||
| Income Tax Expenses | 71.61% | 132.50% | |||
| Earnings from Continuing Operations | 27.98% | -11.46% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -50.00% | -150.00% | |||
| Net Income | 27.96% | -11.63% | |||
| EBIT | 18.77% | -7.94% | |||
| EBITDA | 42.04% | -24.45% | |||
| EPS Basic | 29.20% | -10.52% | |||
| Normalized Basic EPS | 14.64% | -2.63% | |||
| EPS Diluted | 28.91% | -10.08% | |||
| Normalized Diluted EPS | 14.98% | -2.75% | |||
| Average Basic Shares Outstanding | -0.96% | -1.24% | |||
| Average Diluted Shares Outstanding | -1.25% | -1.13% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||